ADHD treatment across the life cycle

Area of Science:

• Neuroscience
• Psychiatry
• Pharmacology

Background:

• Attention-deficit/hyperactivity disorder (ADHD) is frequently diagnosed in childhood.
• A significant proportion of individuals with ADHD experience persistent symptoms into adolescence and adulthood.
• Pharmacologic treatments are established to enhance functional outcomes in pediatric ADHD populations.

Purpose of the Study:

• To review the efficacy of various pharmacologic treatments for attention-deficit/hyperactivity disorder (ADHD) in children, adolescents, and adults.
• To synthesize evidence informing treatment recommendations for adult ADHD based on pediatric data.

Main Methods:

• Review of studies on pharmacologic treatments for ADHD across pediatric and adult populations.
• Analysis of evidence for long-acting methylphenidate, mixed amphetamine salts, desipramine, monoamine oxidase inhibitors, bupropion, and atomoxetine.

Main Results:

• Pharmacologic interventions demonstrate positive results in improving functional outcomes for children with ADHD.
• Similar pharmacologic treatments have shown efficacy in adult ADHD studies.
• Evidence supports the use of reviewed medications in managing ADHD symptoms across developmental stages.

Conclusions:

• Pharmacologic treatments effective in children with ADHD are generally applicable to adolescents and adults.
• The reviewed medications represent key therapeutic options for ADHD management.
• Continued research and evidence synthesis are crucial for optimizing ADHD pharmacotherapy.